Thus, inhibiting CD36 in intra-tumor Tregs through genetic ablation or using CD36 monoclonal antibodies effectively delayed tumor growth and enhanced the efficacy of anti-PD-1 treatment (26). The gene discussed is CD36; the disease is neoplasm.